Oxiselect BPDE DNA Adduct ELISA Kit

Principle of the Assay: BPDE-DNA standards or unknown DNA samples are adsorbed onto a 96-well DNA high-binding plate. The BPDE-DNA adducts present in the sample or standard are probed with an Anti-BPDE-I Antibody, followed by an HRP Conjugated Secondary Antibody. The BPDE-DNA adduct content in an unknown sample is determined by comparing with a standard curve that is prepared from predetermined BPDE-DNA standards.

Background/Introduction: Polycyclic aromatic hydrocarbons (PAHs) are potent, ubiquitous atmospheric pollutants commonly associated with oil, coal, cigarette smoke, and automobile exhaust fumes. Some PAH compounds are also found in cooked foods (e.g. grilled meat, smoked fish) and have been identified as mutagenic and carcinogenic. The toxicity of some PAHs has been demonstrated to induce malignant tumors in animal models and is also commonly believed to significantly contribute to human cancers. One PAH compound, benzo(a)pyrene, is notable for being the first chemical carcinogen to be discovered. Benzo(a)pyrene is a five-ring PAH known to be a procarcinogen; its mechanism of carcinogenesis is dependent on a 3-step enzymatic metabolism (Fig. 1 below) to the final mutagen benzo(a)pyrene diol epoxide (BPDE). Very reactive, BPDE binds covalently to proteins, lipids, and DNA (guanine residues) to produce BPDE adducts. If left unrepaired, DNA adducts may lead to permanent mutations resulting in cell transformation and ultimately tumor development.The OxiSelect™ BPDE DNA Adduct ELISA Kit is an enzyme immunoassay developed for rapid detection of BPDE-DNA adducts. The quantity of BPDE adduct in DNA samples is determined by relative comparison of a known BPDE-DNA standard curve. Each kit provides sufficient reagents to perform up to 96 assays, including standard curve and unknown protein samples.

1. Izzotti A, Rossi GA, Bagnasco M, De Flora S. (1991) Carcinogenesis 12:1281-1285.
2. Denissenko MF, Pao A, Tang M, Pfeifer GP (1996) Science 274:430-432.
3. Lee, B.M. and Santella, R.M. (1988) Carcinogenesis, 9: 1773-1777.
4. Tang D, Phillips DH, Stampfer M, Mooney LA, Hsu Y, Cho S, Tsai WY, Ma J, Cole KJ, She MN, Perera FP. (2001) Cancer Research 61:6708-6712.
5. Mumford JL, Williams K, Wilcosky TC, Everson RB, Young TL, Santella RM. (1996) Mutat Res. 359:171-177.
6. Santella RM, Perera FP, Young TL, Zhang YJ, Chiamprasert S, Tang D, Wang LW, Beachman A, Lin JH, DeLeo VA. (1995) Mutation Research 334:117-124.
7. Chung MK, Riby J, Li H, Iavarone AT, Williams ER, Zheng Y, Rappaport SM. (2010) Anal. Biochem. 400:123-129.

Small volumes of OxiSelect BPDE DNA Adduct elisa kit vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS169130 is a ready-to-use microwell, strip-or-full plate ELISA (enzyme-linked immunosorbent assay) Kit for analyzing the presence of the OxiSelect BPDE DNA Adduct, ELISA Kit target analytes in biological samples. The concentration gradients of the kit standards or positive controls render a theoretical kit detection range in biological research samples containing OxiSelect BPDE DNA Adduct. The ELISA analytical biochemical technique of the MBS169130 kit is based on OxiSelect BPDE DNA Adduct antibody-OxiSelect BPDE DNA Adduct antigen interactions (immunosorbency) and an HRP colorimetric detection system to detect OxiSelect BPDE DNA Adduct antigen targets in samples. The ELISA Kit is designed to detect native, not recombinant, OxiSelect BPDE DNA Adduct. Appropriate sample types may include undiluted body fluids and/or tissue homogenates, secretions. Quality control assays assessing reproducibility identified the intra-assay CV (%) and inter-assay CV(%).